Subtype
Ureter Neoplasm
CI-CAN-00004175Explore in graph →
Non-malignant19 active trials1 evidence items
Loading cancer entity…
Subtype
CI-CAN-00004175Explore in graph →
Clinical trials
71 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03288545 | A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer(EV-103) | terminated | Phase 1 / Phase 2 | 348 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Mar 24, 2026 | clinicaltrials |
| NCT02122172 | Afatinib in Advanced Refractory Urothelial Cancer | terminated | Phase 2 | 32 | University of ChicagoOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT03397394 | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma(ATLAS) | terminated | Phase 2 | 97 | pharmaand GmbHINDUSTRY | 6 | Jun 9, 2023 | clinicaltrials |
| NCT02612194 | LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer | terminated | Phase 2 | 8 | Wake Forest University Health SciencesOTHER | 1 | Nov 3, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Mar 24, 2026source: clinicaltrials